Cellectis (NASDAQ:CLLS) Price Target Cut to $8.00 by Analysts at Robert W. Baird

Cellectis (NASDAQ:CLLS) had its price objective lowered by Robert W. Baird from $10.00 to $8.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price objective would indicate a potential upside of 337.16% from the company’s current price.

Other research analysts have also issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a report on Friday, July 17th. Barclays began coverage on shares of Cellectis in a research report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 target price on the stock. Citizens Jmp restated a “market perform” rating on shares of Cellectis in a research note on Tuesday. Finally, Wells Fargo & Company lowered their target price on Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Cellectis Trading Down 41.0%

CLLS opened at $1.83 on Tuesday. Cellectis has a one year low of $1.75 and a one year high of $5.48. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.37 and a current ratio of 1.37. The stock has a market capitalization of $183.62 million, a PE ratio of -2.82 and a beta of 2.92. The business’s 50 day moving average price is $3.00 and its 200 day moving average price is $3.34.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%. The company had revenue of $6.90 million for the quarter, compared to analysts’ expectations of $11.05 million.

Institutional Investors Weigh In On Cellectis

An institutional investor recently bought a new position in Cellectis stock. Lido Advisors LLC purchased a new position in Cellectis S.A. (NASDAQ:CLLS) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors own 63.90% of the company’s stock.

More Cellectis News

Here are the key news stories impacting Cellectis this week:

• Positive Sentiment: Cellectis plans to focus on in vivo gene-editing treatments for chronic diseases, a strategy that could create a more scalable platform and support longer-lasting therapies. Cellectis Announces Strategic Transformation to In Vivo Gene-Editing Company
• Neutral Sentiment: Citizens JMP reaffirmed its “market perform” rating, indicating limited near-term conviction while the company undergoes the transformation. CLLS Stock Heads for 14-Month Low After 40% Rout
• Negative Sentiment: Cellectis is exiting development of its lasme-cel and eti-cel programs as part of the pivot. Abandoning these cancer programs removes existing pipeline catalysts and contributed to the selloff. Cellectis Announces In Vivo Gene-Editing Transformation
• Negative Sentiment: Citizens JMP flagged delayed catalysts following the cancer-pipeline pivot, suggesting investors may face a longer wait for meaningful clinical or commercial progress. Delayed Cellectis Catalysts After Cancer Pipeline Pivot
• Negative Sentiment: The stock fell below its 50-day moving average and approached a 14-month low, signaling deteriorating momentum and potentially encouraging additional technical selling. Cellectis Share Price Crosses Below Fifty-Day Moving Average

About Cellectis

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.